Ray Dalio Sarepta Therapeutics, Inc. Transaction History

Bridgewater Associates, LP

  • $17.3 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$93.7 - $141.53 $296,654 - $448,083
-3,166 Reduced 12.0%
23,222 $3.01 Million
Q4 2023

Feb 14, 2024
SELL
$67.31 - $124.76 $1.62 Million - $3 Million
-24,076 Reduced 47.71%
26,388 $2.54 Million
Q3 2023

Nov 13, 2023
BUY
$102.5 - $123.59 $2.01 Million - $2.42 Million
19,608 Added 63.55%
50,464 $6.12 Million
Q2 2023

Aug 11, 2023
BUY
$106.4 - $157.19 $41,070 - $60,675
386 Added 1.27%
30,856 $3.53 Million
Q1 2023

May 12, 2023
SELL
$117.53 - $155.99 $3.23 Million - $4.28 Million
-27,465 Reduced 47.41%
30,470 $4.2 Million
Q4 2022

Feb 13, 2023
SELL
$100.86 - $132.13 $4.08 Million - $5.35 Million
-40,473 Reduced 41.13%
57,935 $7.51 Million
Q3 2022

Nov 10, 2022
SELL
$75.71 - $119.24 $2.05 Million - $3.23 Million
-27,110 Reduced 21.6%
98,408 $10.9 Million
Q2 2022

Aug 11, 2022
BUY
$62.69 - $88.44 $7.59 Million - $10.7 Million
121,144 Added 2769.64%
125,518 $9.41 Million
Q1 2022

May 13, 2022
BUY
$63.15 - $90.42 $276,218 - $395,497
4,374 New
4,374 $342,000
Q3 2021

Nov 12, 2021
SELL
$65.97 - $92.48 $253,192 - $354,938
-3,838 Closed
0 $0
Q2 2021

Aug 13, 2021
SELL
$69.38 - $86.75 $25,670 - $32,097
-370 Reduced 8.79%
3,838 $298,000
Q1 2021

May 14, 2021
BUY
$72.25 - $168.95 $304,028 - $710,941
4,208 New
4,208 $314,000

Others Institutions Holding SRPT

# of Institutions
529
Shares Held
84.2M
Call Options Held
2.06M
Put Options Held
1.52M
View Full List

About Sarepta Therapeutics, Inc.

SRPT Quotes by TradingView
  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email